Latest Breaking News On - Junshi bioscience - Page 4 : comparemela.com

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomSan franciscoUnited statesJunshi bioscienceszhi liJunshi bioscienceJunshi biosciencesUniversity cancer hospitalRegulatory agencyRadiographic review committeePr teamJunshi biosciences contact informationir teamNational reimbursement drug listDrug administrationShanghai jiao tong university school of medicineNational medical products administrationEuropean medicines agency

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and comme.

San franciscoUnited statesUnited kingdomJunshi biosciencesZhi liJunshi bioscienceDrug administrationRegulatory agencyIr teamShandong cancer hospital instituteShanghai junshi biosciences co ltdEuropean medicines agencyPr teamGlobal researchNational reimbursement drug listShandong cancer hospital

Toripalimab Plus Chemo Elicits Significant OS Improvement in Recurrent or Metastatic Nasopharyngeal Carcinoma

First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

Junshi bioscienceCoherus biosciencesJunshi biosciencesCoherus biosciences incShanghai junshi biosciences co ltdMaih qChenq yToripalimab in combination with gemcitabine and cisplatinPatients with recurrent or metastatic nasopharyngeal carcinomaJupiter 02 trialJennifer choeVanderbilt university medical center

Sub: Transcript of the Earnings call conducted on May 10, 2023 - Form 6-K

Sub: Transcript of the Earnings call conducted on May 10, 2023 Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015, please find enclosed the. | May 16, 2023

New zealandUnited statesUnited kingdomDamayanti keraiParag agawwalAshish thavkarAnkush mahajanSurya patraKunal dhameshaCyndrella carvalhoTushar manudhaneK randhir singhRicha periwalPrakash agarwalMayne pharmaNitin agarwal

Junshi Biosciences Announces Collaboration with Dr Reddy s to Develop and Commercialize Toripalimab in 21 Countries

SHANGHAI, China, May 07, 2023 Shanghai Junshi Biosciences Co., Ltd announced a collaboration with Dr. Reddy’s Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1. | May 7, 2023

United kingdomNew zealandSouth africaAndhra pradeshUnited statesSan franciscoZhi liJunshi biosciencesJunshi bioscienceNational stock exchange of indiaYork stock exchangeGood health cant waitIr teamNational reimbursement drug listBombay stock exchangePr team